We next examined the associations between ACLY expression levels and patients’ survivals using the TCGA clinical data.[20] The analyses revealed that the patients with relatively higher ACLY expression showing significantly poorer overall survival (OS) than those with lower ACLY expression in breast, lung, liver, bladder, head and neck, and cervical cancers (all p<0.05). Here, ACLY is linked to cervical cancer.